July 23 (Reuters) - Novo Nordisk's

weight-loss drug Wegovy has secured the UK regulator's approval

for its use to reduce the risk of overweight and obese adults

suffering serious heart problems or strokes, the agency said on

Tuesday.

Approval from UK's Medicines and Healthcare products

Regulatory Agency makes Wegovy the first GLP-1 weight-loss drug

to be prescribed for prevention of cardiovascular events in

people with obesity.

The decision follows a similar nod from the U.S. Food and

Drug Administration in March.